Scopus
YÖKSİS DOI Eşleşti
SJR Q1
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
Veterinary Journal · Ekim 2025
YÖKSİS Kayıtları
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
The Veterinary Journal · 2025 SSCI
Arş. Gör. ZEKERİYA SAFA İNANÇ →
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
The Veterinary Journal · 2025 SCI-Expanded
Doç. Dr. DURMUŞ HATİPOĞLU →
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
VETERINARY JOURNAL · 2025 SCI-Expanded
Prof. Dr. BURAK DİK →
YÖKSİS Kayıtları — ISSN Eşleşmesi
Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co administration in healthy and endotoxaemic rabbits
2008 ISSN: 10900233 SCI-Expanded
Prof. Dr. MUAMMER ELMAS →
Effect of Experimental Therapeutic Ultrasound on the Distal Antebrachial Growth Plates in One Month Old Rabbits
2002 ISSN: 10900233 SSCI
Prof. Dr. İLHAMİ ÇELİK →
Effect Of Experimental Therapaeutic Ultrasound On The Distal Antebrachial Growth Plates In One Month Old Rabbits
2002 ISSN: 1090-0233 SCI
Prof. Dr. MURAT BOYDAK →
Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits
2008 ISSN: 10900233 SCI-Expanded
Prof. Dr. ENVER YAZAR →
Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co administration in healthy and endotoxaemic rabbits
2008 ISSN: 10900233 SCI-Expanded 12 atıf
Prof. Dr. KAMİL ÜNEY →
Effect of experimental therapeutic ultrasound on the distal antebrachial growth plates in one-month-old rabbits
2002 ISSN: 1090-0233 SCI-Expanded
Prof. Dr. FAHRETTİN ALKAN →
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
2025 ISSN: 1090-0233 SSCI Q1
Arş. Gör. ZEKERİYA SAFA İNANÇ →
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
2025 ISSN: 1090-0233 SCI-Expanded Q1
Doç. Dr. DURMUŞ HATİPOĞLU →
Liraglutide as a novel therapeutic for overweight in canines: A clinical study
2025 ISSN: 1090-0233 SCI-Expanded Q1
Prof. Dr. BURAK DİK →
Makale Bilgileri
Dergi
Veterinary Journal
ISSN10900233
Yayın TarihiEkim 2025
Cilt / Sayfa313
Scopus ID2-s2.0-105006914912
Özet
Background: The overweight/obesity in dogs is defined as a condition of abnormal fat accumulation or, beyond that, a multifactorial condition involving excessive fat accumulation along with different factors (insufficient physical activity, genetics (breed), metabolism, the microbiome, etc.). Preclinical obesity conditions increases the risk of progressing to clinical obesity and developing obesity-associated diseases such as type 2 diabetes, cardiovascular disease, certain cancers, and mental disorders. Objectives: This study aimed to determine the weight-loss effects of liraglutide in dogs that do not engage in sufficient exercise, are fed table scraps, and develop obesity owing to aging. Animals: In this study, 21 senior Golden Retriever dogs were divided into three equal groups. Methods: Group 1 was considered healthy and consisted of dogs within the range of ideal body live weight and body condition scores, and fed dry commercial dog food at the amount of their daily metabolizable energy requirements. Group 2 included seven senior dogs with obesity fed commercial dry food adjusted for their daily metabolizable energy requirements. Group 3 comprised seven senior dogs with obesity fed commercial dry food adjusted for their daily energy requirements and concurrently treated with subcutaneous liraglutide at a dose of 1.2 mg/dog. The trial lasted for 40 days. Results: Liraglutide treatment resulted in a decrease in body condition score (BCS) and body weight by day 40, although the reduction in body weight (13.27 %) did not reach statistical significance. Liraglutide significantly lowered cholesterol and triglyceride levels, and appetite tests revealed a marked suppression of food intake over consecutive days in treated dogs. Conclusions and clinical importance: Liraglutide treatment may offer a viable option for treating obesity in dogs, and could potentially be used as a new anti-obesity drug in canines. Future long-term and detailed trials of liraglutide in dogs with obesity could facilitate its effective use in the field.
Yazarlar (7)
1
Burak Dik
2
Durmus Hatipoglu
ORCID: 0000-0003-3790-7821
3
Oğuzhan Kahraman
ORCID: 0000-0002-9315-5276
4
T. M. Parlak
5
Zekeriya Safa İnanç
6
Metin Celik
7
S. Damar
Anahtar Kelimeler
Canine
GLP-1
Liraglutid
Overweight
Kurumlar
Erciyes Üniversitesi
Kayseri Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Scimago Dergi (ISSN Eşleşmesi)
Veterinary Journal
Q1
SJR Skoru0,739
H-Index139
YayıncıBailliere Tindall Ltd
ÜlkeUnited Kingdom
Animal Science and Zoology (Q1)
Veterinary (miscellaneous) (Q1)
Metrikler
2
Atıf
7
Yazar
4
Anahtar Kelime